- Corporate
Overview
Due
to the high morbidity and mortality associated with infections caused by multidrug-resistant
bacteria, such as Staphylococcus aureus, Enterococcus faecalis, Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae the discovery of innovative
agents with potent activity against these pathogens is the top priority of our
anti-infectives research team.
Exploratory programs
Basilea
scientists are exploiting their expertise in beta-lactam chemistry to advance
research into innovative antibiotics that can resist attack by beta-lactamases
and to discover new inhibitors of beta-lactamases that could be used to restore
the activity of antibiotics against which bacteria have developed resistance.
Basilea is also pursuing novel macrolides applying expertise developed during the identification and characterization of BAL19403, a macrolide with potent activity against Propionibacterium acnes, including many resistant strains. Further exploratory research projects are focused on finding novel inhibitors that work on targets not exploited by currently marketed antibiotics and should therefore avoid specific resistance mechanisms.
© 2013 Basilea Pharmaceutica Ltd.
